Oppenheimer reiterates Nektar stock rating on alopecia data By Investing.com

Nektar shares have returned 653% over the past year and trade at $76.23 (near a 52-week high of $77.97); Oppenheimer reiterated Outperform and raised its price target to $140 while Wedbush initiated Neutral at $70 and TD Cowen started with a Buy implied NPV of $109. The company presented detailed Phase 2b REZOLVE‑AA data at AAD 2026 and expects blinded 16‑week extension results in April; initial topline REZOLVE‑AA reaction in December was negative and InvestingPro flags the stock as overvalued. The April extension could inform Phase 3 design and the alopecia areata opportunity but is unlikely to be a decisive binary given small sample size.

Analysis

Market pricing already bakes in a high-probability positive read on rezpeg’s alopecia program — the stock is trading with option-like upside into an April extension update despite that sample being small and entry-criteria selected. That mismatch creates a binary skew: a clean directional improvement would likely compress implied volatility and drive another leg up, whereas a neutral/noise result can erase a large portion of the recent rally because the market is paying for precision it won't get from a small cohort.

Second-order winners if rezpeg scales: CDMOs and single-use bioprocess suppliers will see capacity pull-forward risk, and payers will push hard for comparative evidence versus incumbent JAK inhibitors, which reduces pricing leverage for a biologic in this indication. Conversely, incumbents in the oral JAK class face a demand-share hit only if rezpeg shows convincingly superior safety or durability in larger cohorts — until then, prescribers and PBMs have incentives to stick with established, cheaper oral options.

Timing and tail risks are asymmetric: near term (days–weeks) volatility is event-driven around the April 16-week update; medium term (3–12 months) Phase 3 design readouts and payer signals matter; long term (2+ years) manufacturing scale and label/safety profile determine commercial upside. The consensus is underestimating variance from small cohorts and overestimating the immediacy of payer willingness to accept a premium biologic for an indication dominated by lower-cost orals.

Key Decisions for Investors

• Event call spread: Buy NKTR Apr (post-update) call spread (buy nearer-term ITM/ATM, sell higher strike 4–6 weeks out) sized to risk 0.5–1.0% of portfolio — asymmetric 2–3x upside if update signals durable benefit, max loss = premium paid.
• Long shares with protection: Accumulate NKTR size-limited (1–2% portfolio) and buy 8–12 week puts ~25–30% OTM as a tail hedge; rationale: preserves upside into Phase 3 design signals while capping drawdown from a noisy negative reaction.
• Pair trade to capture class uncertainty: Go long NKTR (smaller size) / short LLY (size accordingly) for 3–6 month horizon to express rezpeg-specific upside vs JAK incumbent exposure; unwind if payer commentary or larger safety signals emerge.
• Avoid naked long gamma: Do not own large-sized long-dated NKTR calls pre-April without hedges — implied vol is rich and the sample-size nature of the update makes it a high probability of post-event mean reversion; prefer defined-risk structures.